Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-08-29
2006-08-29
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
Reexamination Certificate
active
07098006
ABSTRACT:
An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.
REFERENCES:
patent: 4652447 (1987-03-01), Kung et al.
patent: 4695459 (1987-09-01), Steinman
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545403 (1996-08-01), Page
patent: 200412 (1986-10-01), None
patent: 239400 (1987-09-01), None
patent: 328404 (1989-02-01), None
patent: 0 323 806 (1989-07-01), None
patent: 0 327 000 (1989-08-01), None
patent: 365209 (1989-10-01), None
patent: 380018 (1990-01-01), None
patent: 409242 (1990-07-01), None
patent: 403156 (1990-12-01), None
patent: 861533 (1986-03-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/09622 (1989-10-01), None
patent: 9007861 (1990-07-01), None
patent: 9107492 (1991-05-01), None
patent: 9109966 (1991-07-01), None
patent: 9109967 (1991-07-01), None
Mathieson et al. [New England Journal of Medicine 323(4):250-254 (1990)].
Bruggemann, et al.,J. Exp. Med.,1987, pp. 1351-1361.
Burgess, et al.,The Journal of Cell Biology, 111(1990), pp. 2129-2138.
Byrn et al.,Nature, 344,1990, pp. 667-670.
Crowe et al.,Nucleic Acid Research, 17,1989, p. 7992.
Daugherty et al.,Nucleic Acids Research, 19,1991, pp. 2471-2476.
Gorman et al.,Proc. Natl. Acad. Sci. USA, 88,1991, pp. 4181-4185.
Kettleborough, et al.,Protein Engineering,4:7, 1991, pp. 773-784 (ABST.).
Lewis, et al.,Gene, 101,1991, pp. 297-302.
Orlandi et al.,Proc. Natl. Acad. Sci. USA, 86,1989, pp. 3833-3837.
Queen et al.,Proc. Natl. Acad. Sci. USA, 86,1989, pp. 10029-10033.
Reichmann, L., et al.,Nature, 332,1988, 323-327.
Roberts et al.,Nature, 328,1987, pp. 731-734.
Sharon,Proc. Natl. Acad. Sci. USA, 87,1990, pp. 4814-4817.
Tao, et al.,Journal of Immunology, 143(8), 1989, pp. 2595-2601.
Verhoeyen et al.,Science, 239,1988, pp. 1534-1536.
Waldmann,Science, 252,1991, pp. 1657-1662.
Ward et al.,Nature, 341,1989, pp. 544-546.
Jones et al.,Nature, 321(1986), pp. 522-525.
Lazar et al.,Molecular and Cellular Biology, 8(3), 1247-1252, 1988.
Sambrook, “Oligonucleotide-mediated Mutagenesis”, Molecular Cloning 2ndEd. 15.51-15.56 (1989).
Carteron et al, “Treatment of Murine Lupus with F(ab')2Fragments of Monoclonal Antibody to L3T4”, J. Immunol. 142:1470-1475 (1988).
Gorman and Clark, “Humanisation of monoclonal antibodies for therapy”, Seminars in Immunology 2:457-466 (1990).
Carter et al, “Improved oligonucleotide side-directd mutagenesis using M13 vectors”, Nucleic Acids Research 13(12):4431-4443 (1985).
Panayi et al, “T Cell Hypothesis in Rhematoid Arthritis (RA) Tested By Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment I: Suppression of Disease Activity and Acute Phase Response ”, Arthritis & Rheumatism 39(9)(Supplement):S244 (1996), Abstract No. 1300, Abstract Supplement, 1996, National Scientific Meeting, Orlando, Florida, Oct. 18-22, 1996.
Choy et al, “T Cell Hypothesis in Rheumatoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment II: Clinical Activity is Related to Pharmacodynamic Effects”, Arthritis & Rheumatism 39(9)(Supplement):S244 (1996), Abstract No. 1301, - Abstract Supplement, 1996 National Scientific Meeting, Orlando, Florida, Oct. 18-22, 1996.
Connolly et al, “T Cell Hypothesis in Rhematoid Arthritis (RA) Tested by Humanized Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment III: Immunological Effects”, Arthritis & Rheumatism 39(9)(Supplement):S245 (1996), Abstract No. 1302, - Abstract Supplement, 1996 National Scientific Meeting, Orlando, Florida, Oct. 18-22, 1996.
Choy et al, “T Cell Hypothesis in Rhematoid Arthritis (RA) Tested by Humanised Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment II: Clinical Activity is Related to Pharmacodynamic Effects”, Immunology 89(Supplement 1):92 (1996), Abstract No. Ogg378—Joint Congress of The British Society for Immunology and The Biochemical Society, Harrogate, UK, Dec. 10-13, 1996.
Panayi et al, “T Cell Hypothesis in Rhematoid Arthritis (RA) Tested by Humanised Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) Treatment I: Suppression of Disease Activity and Acute Phase Response ”, Immunology 89(Supplement 1):92 (1996), Abstract No. Ogg379—Joint Congress of The British Society for Immunology and The Biochemical Society, Harrogate, UK, Dec. 10-13, 1996.
Choy et al, “Effect of a Humanised Non-Depleting Anti-CD4 Monoclonal Antibody (mAb) on Synovial Fluid (SF) in Rheumatoid Arthritis (RA) ”, Arthritis & Rheumatism 40(9)(Supplement):S52 (1997), Abstract No. 130, -Abstract Supplement, 1997 National Scientific Meeting, Washington, DC, Nov. 8-12, 1997.
Werther et al, “Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1”, The Journal of Immunology 157:4986-4995 (1996).
Presta et al, “Humanizationof an Antibody Directed Against IgE”, The Journal of Immunology 151(5):2623-2632 (1995).
Cunningham et al, “Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis”, Research Articles, pp. 1330-1336 (1989).
Rostapshov et al., “Effective method for obtaining long nucleotide chains on partially complementary templaces”, 249(2):379-382 (1989).
Decision revoking the European Patent (Article 102(1)EPC), Appln. No./Patent No. 91 907 669.5-2116/0549581, Nov. 2, 2000.
Clark Michael Ronald
Cobbold Stephen Paul
Gorman Scott David
Waldmann Herman
Burroughs Wellcome Co.
Helms Larry R.
Nixon & Vanderhye P.C.
LandOfFree
Chimeric antibody, pharmaceutical composition and process of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antibody, pharmaceutical composition and process of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antibody, pharmaceutical composition and process of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3663551